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Abstract 
Background: Biobanking provides exciting opportunities for research on stored biospecimens. However, these 
opportunities to advance medical science are fraught with challenges including ethical and legal dilemmas. This 
study was undertaken to establish perspectives of South African stakeholders on the ethico-legal dimensions of 
biobanking.
Methods: An in-depth exploratory study was conducted with 25 purposively selected biobankers, clinicians, 
researchers, postgraduate students in biobanking research, and research ethics committee (REC) members in South 
Africa. Potential study participants were recruited through known hubs for biobanking in the country, online searches 
and the snowball sampling technique. A semi-structured face-to-face or Skype interview was arranged. Data was 
analysed using thematic analysis.
Results: The emergent themes included: inconsistency in understanding consent models, disconnect between 
biobank researchers and biosample donors, inadequate processes to support re-consenting minors, inconsistent 
governance processes for biobanking research; challenges with sample and data sharing, and suboptimal strategies 
for benefit sharing and return of results. Biobanking practice in general appeared to be inconsistent and fragmented. 
While the need for consent in research is explicitly outlined in legislative documents, some respondents were unclear 
on the type of consent model to apply in biosample collection. They also reported inconsistencies in research par-
ticipants’ understanding of consent. Furthermore, these respondents’ own understanding of consent and consent 
models were dependent on where they were positioned in biobanking practice (roles occupied). Respondents were 
unsure about the process to follow to re-consent child participants once the age of majority (≥ 18 years) was reached. 
It was not surprising that consent was identified as one of the major ethical challenges in biobanking practice. In 
certain settings, some respondents reported suboptimal governance processes for sample collection. Participants 
were generally unsure about how to operationalise benefit sharing and how to approach the idea of returning results 
to research participants and biobank donors.
Conclusion: The study findings indicated inconsistencies in stakeholder understanding of ethico-legal considera-
tions related to biobanking in South Africa. A need for ongoing ethics capacity development among stakeholders was 
identified. Improving understanding of the ethics of biobanking could be facilitated by acknowledging the discon-
nect created by biosamples in the relationship between biobank researchers and donors.
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Background
The conduct of biomedical research involving the collec-
tion, use, storage and export of well-annotated human 
biological material has generated considerable debate 
in South Africa, given the associated ethical and legal 
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complexities [1–4]. While the National Health Act (Act 
61 of 2003) (NHA) makes provision for the regulation of 
tissue banking and transplantation in South Africa [5], 
the provision for biobanking in the Act, is notably absent 
[6]. The lack of clear legislation in this field creates a 
loophole for different interpretations of the law and given 
South Africa’s history of exploitation and human rights 
violations, greater scrutiny and more robust and explicit 
guidance and legislation are required on the ethical and 
legal aspects of biobanking. Despite South Africa’s tran-
sition to democracy (post 1994), social and economic 
inequalities persist creating a fertile ground for health 
inequities that could open a gateway for continuing 
exploitation. One such case is the recent publicized dis-
pute between an academic institution in South Africa and 
the Wellcome Sanger Institute in the UK over the alleged 
commercialization of transferred biological material and 
data, intended and consented for research purposes only 
[7–9]. To elaborate, a South African research site initially 
shared samples with a university in the United States 
(US) through a research collaborative initiative. This was 
done with the necessary export permits in place for the 
cross border transfer of samples and with the affected 
research participants’ consent. The shared samples were 
subsequently transferred to the Wellcome Sanger Insti-
tute for research-related genome analysis, as part of the 
agreed material transfer agreement (MTA) between the 
South African institution and the university in the US. 
The contention arose when the samples were allegedly 
further shared by the Wellcome Sanger Institute with a 
third party for the creation of gene chips (also known as 
‘microarrays’ for rapid genetic testing) but without the 
original South African university’s knowledge nor with 
consent from research participants. Additionally, the 
South African university claimed that there was no data 
sharing agreement with this third party and demanded 
the return of the shared samples from the Wellcome 
Sanger Institute [7, 10, 11].
The extent to which researchers balance scien-
tific imperatives in knowledge advancement through 
biobanking research while upholding ethical obligations 
to research particpants, affected communities and par-
ticipating institutions, remains unclear [3, 12]. This is of 
particular interest given that communities such as the 
San people of sub-Saharan Africa have shown greater 
awareness of exploitation in research and have responded 
with a community-driven ethical code of conduct for 
research [13].
Biobanking practice in South Africa ranges from small 
scale research projects located within academic and 
research-based institutions to large scale archived diag-
nostic samples stored within teaching hospitals; estab-
lished biobanks in public/academic settings; private 
non-profit registeries and profit-based cord and stem 
cell tissue banks [6]. The multi-disciplinary nature 
of biobanking research adds to this debate given that 
stakeholders (both direct and indirect) emerge from 
diverse disciplines such as science, medicine, law, genet-
ics,  genomics,  bioethics, technology and bioinformat-
ics [14]. This diversity reflects a complex landscape in 
biobanking-related activities but little is known about 
how stakeholders engage with context-specific ethical 
challenges in biobanking research in South Africa. Some 
of the known ethical challenges include participants’ 
rights to privacy and confidentiality, autonomy, return 
of results, benefit sharing and secondary use of biospeci-
mens and data [3, 15]. The extent to which researchers 
and funders engage in commercialization of biosamples 
in public and academic biobanking efforts remains largely 
unknown.
Given this incomplete picture of stakeholder involve-
ment in the context of legislative lacunae, the purpose 
of this study was to understand stakeholder perspectives 
on ethico-legal considerations in biobanking practice in 
South Africa. This study forms part of a larger project 
on the ethical, legal and social issues  associated with 
genomic and biobanking research [16–19].
Methods
This was an in-depth exploratory study using a qualita-
tive approach to engage with stakeholders involved in 
biobanking in an attempt to seek their perspectives on 
ethico-legal considerations in contextualised settings. 
In this study, stakeholders were defined as individu-
als (biobankers, researchers, clinicians, nurses) involved 
in the operationalization and/or oversight of managing 
stored biological material, or in the ethics review of such 
related research (research ethics committee/REC mem-
bers). The study excluded stakeholders such as policy 
makers, funders and research participants.
There are specific groups of individuals involved in 
biobanking practice and health research ethics related 
to biobanking in the country, therefore a purposive sam-
pling technique was used to identify the various hubs for 
biobanking practice and research ethics review in the 
country. All identified individuals in the biobanking hub 
were also requested to link the researchers with other 
stakeholders involved in biobanking and research ethics 
review. Thus, a  snowball sampling  technique was also 
used. Additionally, online searches and literature reviews 
were conducted to further identify stakeholders beyond 
the existing network of people involved in biobanking to 
ensure a wide representation of the study sample.
The study population thus comprised biobankers, clini-
cians, researchers, postgraduate students in biobanking 
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research, and REC members. A semi-structured face-to-
face or Skype interview was conducted with the identi-
fied stakeholders (n = 25) (Table 1).
It was noted that study participants could occupy 
more than one role, such as biobanker, researcher, REC 
member and clinician as reflected in Table  1. Letters of 
invitation for participation in the  study were sent to all 
identified individuals in these hubs. All interested indi-
viduals were requested to contact the researchers if they 
expressed interest in participation in the study. The inter-
view was arranged, based on the participant’s availability 
and willingness to participate in the study, and after writ-
ten informed consent was obtained, during the period: 
January 2019 to August 2019. The interview was approxi-
mately 30–60 min in duration and was digitally recorded.
The interview focused on the following topics: ethical 
challenges facing biobanking practice in South Africa and 
stakeholder perspectives on improving understanding of 
research in this area. Further probing during the inter-
view focused on participants’ understanding of consent, 
return of results and benefit sharing. These probes were 
included because the identified issues are poorly defined 
in existing South African guidelines. Given the general 
inability of some study participants to engage with the 
identified issues during the interview, a follow-up inter-
view (via email) was conducted with 4 study participants 
with expertise in biobanking, to seek clarity on benefit 
sharing and return of results for biobanking research.
Thematic analysis was used to analyze the textual and 
contextualised opinions on biobanking practice to pro-
duce arguments that could reinforce or undermine the 
study participant’s position or point of view [20]. Narra-
tives from the interviews were coded and analyzed using 
ATLAS.ti 8 Windows software package. Data was first 
recorded verbatim and a transcript was created for each 
interview. This was cleaned before the analytical pro-
cess. Familiarization of the data entailed reading through 
a descriptive narrative of each participant’s perspective. 
Initial coding of data was conducted to build a coding 
frame. Codes were then defined, reviewed, collated and 
organised into code groups. Each code group was fur-
ther examined for patterns and emergent themes. These 
themes were named and further examined to identify 
patterns and linkages between the themes. The research-
ers also identified quotes in the study participants’ tran-
scripts that were congruent with the overarching themes. 
The emergent themes from data analysis were further 
reviewed and then compared with the available literature. 
This contributed to transferability of the data collected 
and allowed for extrapolation of the research findings to 
other similar settings. A co-coder was used and themes 
were identified independently and then compared and 
agreed upon. Member verification was also conducted to 
ensure that the collected data was a true reflection of the 
participant’s statements on biobanking practice.
Results
Given the heterogeneity of biobanking practices, it was 
not surprising that there was a wide range of experiences 
and perceptions among study participants. The themes 
arising from this study included inconsistency in under-
standing consent models, disconnect between biobank 
researchers and biosample donors, inadequate support 
for the re-consenting process for minors involved in pro-
viding samples for biobanking; inconsistency in govern-
ance processes for biobanking research; challenges with 
sample and  data sharing, and suboptimal strategies for 
benefit sharing and return of results.
Biobanking practice in general appeared to be incon-
sistent, fragmented and poorly defined. Perceptions on 
the state of biobanking varied from well organized facili-
ties (according to biobankers) to ad hoc unclear processes 
for collection and distribution of biospecimens (accord-
ing to researchers, post graduate students, REC members 
and clinicians).
Table 1 List of respondents
Interviewee Position/Experience
1 Researcher, biobanker, REC member University A
2 Researcher, University B
3 Clinical care, nurse, University B
4 REC member, research ethics teaching University B
5 Clinician, researcher, biobanker, University B
6 Researcher, biobanker, University B
7 Retired: Research ethics
8 Clinician, researcher, biobanker, University B
9 Researcher, research ethics, University B
10 Researcher, REC member, University A
11 Retired: research ethics, REC member
12 Clinician, researcher, biobanker, University B
13 Researcher, clinician, REC member, University A
14 Researcher, REC member, University A
15 REC member, researcher, University A
16 Researcher, REC member, University A
17 Researcher, postgraduate student, University A
18 Researcher, biobanker, University A
19 Researcher, post graduate student, University  A
20 Researcher, postgraduate student, University A
21 Researcher, research ethics, University D
22 REC member, University D
23 Research ethics, University D
24 REC member, University D
25 Researcher, biobanker, University C
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In response to the question: What is the state of 
biobanking practice in the country?, more than two thirds 
of the study sample (researchers, clinicians, biobankers 
and REC members) believed that the climate of biobank-
ing in South Africa was punctuated by a general lack of 
understanding among researchers, clinicians, research 
participants and communities on the exact nature and 
purpose of biobanks, biobanking and biorepositing of 
samples.
We are talking about secondary use,… data  
and  sample transfer across borders and these are 
complex things, especially in our setting in Africa, 
taking into account all our different cultures and 
traditions. And also the lack of understanding, you 
don’t really want to say lack of education because 
even the educated person still has the opinion that 
biobanking is just [about] storage in freezers, which 
it is not (6).
The notion of respect for research participants and 
communities emerged as a key ethical consideration in 
biobanking practice.
Inconsistency in understanding consent models
In response to the question: What are the ethical chal-
lenges in biobanking practice in the country? some of the 
reported ethical challenges included the consent pro-
cess for obtaining the biosample (specifically in relation 
to research participants’ understanding of the research 
purpose or their anxiety associated with the extraction 
of biosamples) and re-consenting processes for samples 
taken from children (< 18  years of age). The study find-
ings suggested that some respondents had challenges 
with the process of obtaining consent from research 
participants but failed to identify the different consent 
models in biobanking research. Given that study par-
ticipants occupied multiple roles in  biobanking practice 
(researcher, clinician, biobanker, REC member), these 
multi-fold challenges further highlighted the complexity 
in biobanking research.
From a legal perspective, the National Health Act 
(NHA) (Act 61 of 2003) replaced the Human Tissue Act 
No 65 of 1983 in South Africa and now regulates the 
use, collection and disposal of human biological sam-
ples such as tissues, blood and blood products, and 
gametes [5]. Research participants’ rights to autonomy 
are enshrined in the NHA:   Sect.  71(1) [5]. Similarly, 
Chapter II (Sect. 14) of the South African Constitution 
highlights the right to privacy as a fundamental right. 
More recently, South Africa adopted the Protection of 
Personal Information Act 4 of 2013 (POPIA), which 
came fully into effect from July 2020. Section  13(1) 
of POPIA (2013) outlines that personal information 
[which would include biometric information and 
DNA analysis] must be collected for a ‘specific, explic-
itly defined and lawful purpose’. Section  15 of the Act 
specifies that further processing of samples for research 
must be compatible with the original purpose for which 
it was collected [21]. Thus POPIA provides a constitu-
tional right to privacy and highlights the need for data 
security, participant confidentiality and access to infor-
mation [21].
While POPIA specifies the need for specific con-
sent, broad consent and other consent models are sup-
ported in national guidelines such as the South African 
Department of Health’s Ethics in Health Research: 
Principles, Processes and Structures (DOH 2015) [22]. 
These two documents could be seen as contradictory 
thus could contribute to a lack of clarity in terms of the 
type of consent to be used in biobanking. Given that 
POPIA has only been fully implemented in 2020 and 
that legislative processes still allow for an additional 
year for public comment and stakeholder input, there is 
no doubt that there is a need for alignment of national 
processes and guidelines related to consent for research 
purposes.
While the legal position for consent in research is 
clearly defined (as articulated by NHA), the type of 
consent model to be used in biobanking remains vague. 
It was therefore not surprising that there were varied 
responses in this study to the type of consent required 
for storage of biospecimens but more importantly there 
was inconsistency among study participants in under-
standing the type of consent model to be used in the 
collection of biosamples.
The divergent understandings of consent further 
articulated a contrast between the legal position and 
what actually happens in biobanking practice. Study 
participants (researchers, clinicians, REC members) 
indicated that the storage of biosamples for unknown 
future use had ethical implications. The notion of con-
sent, however was seen more as a technical process 
without due consideration to the different models of 
consent and implications for the biobank research 
participants’ autonomy and privacy. This is of particu-
lar importance given the dual roles that a clinician/
researcher could occupy and that risks associated with 
future unknown use of biosamples could differ from 
those in clinical settings.
In response to the questions, What are some of the 
consent models used in biobanking? What could be  the 
associated ethical challenges?, broad consent, dynamic 
and tiered consent models were identified, but at least 
six out of the twenty-five (6/25) participants were una-
ware of the different consent models in biobanking 
research.
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The big ethical challenge that we have is that peo-
ple are very used to broad consent and haven’t 
really been held to account for what participant 
information they provide, and now with the POPI 
Act coming up that’s not going to be acceptable 
anymore. I think people are pushing… research-
ers don’t like to make a change when they are used 
to something being the way it is, and I hear lots 
of moaning about how this is going to shut down 
genomics (21).
Disconnect between biobank researchers and biosample 
donors
This theme indicated that understanding the notion of 
consent or the models of consent used, was very much 
dependent on where the respondent was positioned in 
biobanking practice, and how this could possibly influ-
ence ethics oversight in biobanking. A respondent at 
the forefront of the primary collection site was able to 
articulate the process of obtaining consent from the 
research participant. A respondent dealing with the 
stored biosample had little interaction with the actual 
research participant or donor.
When people work with the sample they don’t look 
at its purpose, they just see it as colourless liquid 
and I think that it would be nice [to remember] 
that this actually belongs to a human being, and 
we are just the custodians of the sample, and that 
we should have respect when we use it (12).
Respondents (researchers, clinicians, REC members) 
identified a disconnect between the collected biospeci-
men and the individual who provided the biosample, 
where the focus was on the biosample without due con-
sideration that the sample was obtained from a human 
being. Part of the reported challenges included con-
cerns about researchers who dealt only with the bio-
specimens and were not directly involved in the clinical 
collection point at the interface with research partici-
pants or biosample donors. Respondents (researchers, 
postgraduate students, a  nurse, clinicians, biobank-
ers, REC members) thought that respect had to apply 
to both the individual research participant and his/her 
collected biospecimens.
Thus the physical distance between research partici-
pants or biosample donors (at the sample collection 
point) and the biobank could paradoxically create a dis-
tance in the relationship between biobank researchers 
and donors. This suggests that ethics oversight could 
be diluted because of the lack of direct accountability. 
This distance could be increased when the samples are 
shared with other researchers, thus suggesting a further 
dilution of ethics oversight and accountability.
Consent for biobanking specimens from minors
Some respondents (researchers, clinicians, REC mem-
bers) also highlighted ethical challenges that could arise 
when specimens taken from minors (< 18 years of age) 
are collected for biobanking purposes. The NHA stipu-
lates that parental or legal guardian consent is required 
for child participants (< 18  years of age) in research. 
Ethical dilemmas can arise when children reach the age 
of independent consent (≥ 18  years). Should the child 
participant (now an adult) be re-consented?
The NHA also made provisions for the creation of 
the National Health Research Ethics Council (NHREC) 
which is a statutory body responsible for research eth-
ics oversight as well as the registration of RECs  in 
South Africa. According to the NHA, Sect.  72(1); 
responsibility is given to RECs (that are registered with 
the NHREC) within South Africa to review and approve 
such research, when all criteria for participant protec-
tion are met [5].
Additionally, the South African Department of 
Health’s Ethics in Health Research: Principles, Pro-
cesses and Structures (DoH 2015) [22] highlights that 
ministerial permission is required for the ‘removal of 
biological materials from mentally ill persons; or mate-
rials taken from a minor that are not naturally replace-
able and that no foetal biological material except for 
umbilical cord progenitor cells may be collected from 
anyone’ [22]. While the guideline mentions re-consent 
in general, there is no clarity on how this should be 
implemented. While these stipulated conditions for the 
removal of biological material from mentally incapaci-
tated persons or minors are meant to protect the iden-
tified populations, the use of such nomenclature could 
also create possible confusion. One such example could 
be that while blood is replaceable, such procedures are 
also invasive.
The study findings suggested a further disconnect 
between the legal position and study participants’ 
awareness of these support structures. Attention should 
also be drawn to the inadequacies of national guidelines 
such as Ethics in Health Research: Principles, Processes 
and Structures (DOH 2015) [22] to provide clarity on 
the process of re-consenting minors for biobanking 
research.
Study participants (researchers, clinicians, REC 
members) raised questions on whether and how re-
consenting should occur once these participants 
reached the age of independent consent (age 18 and 
above in South Africa). Study participants were unsure 
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on how to re-consent these participants nor was 
there reported clarity on the process of re-consenting.
“…in our kind of context especially in studies that 
involve minors who may reach the age of majority 
during the sample storage period, how actually is 
that managed because it is difficult to often con-
tact participants down the line? How do research-
ers ensure that they are able to get consent from 
minors when they reach the age of majority? (24).
RECs should be an important resource for researchers 
requiring clarity on ethical issues related to biobanking, 
provided that these committees have the capacity and 
skills mix to handle such queries.
Inconsistencies in governance processes for biobanking 
research
There were inconsistencies reported in the governance 
of biobanking in the country. Biobankers believed that 
biobanking initiatives were good and  reported efforts 
made to strengthen biobanking governance in South 
Africa through collaborative networks such as ISBER and 
initiatives driven by the H3Africa consortium. There was 
a perception that biobanking governance in these settings 
was underpinned by best practices.
Concurrently some biorepositing efforts appeared 
unstructured and poorly defined (those reported by 
postgraduate students), thereby suggesting inadequate 
governance processes in certain settings. This clearly 
implied differences in the nature of biobanking efforts 
across different settings and that the governance (col-
lection and processing) of biospecimens was very much 
dependent on the contextualized setting. Study par-
ticipants (postgraduate students) reported challenges 
encountered when travelling from academic institutions 
to community-based health facilities for the extraction, 
and transport of collected biosamples. There were vague 
processes in place to support collection of biospecimens 
under these conditions. Some of the reported chal-
lenges  encountered   by postgraduate students included 
incomplete clinical records for documenting informa-
tion, incorrect processes for labelling of biospecimens, 
and unclear tracking systems for biospecimens. Trans-
portation of biospecimens was identified as a challenge 
specifically when postgraduate students were involved 
in the collection and transfer of biosamples for research 
purposes. Study participants (postgraduate students) 
reported having no option but to use public transport 
facilities to ferry biosamples from the collection points 
(hospitals) to the clinical laboratories (university settings) 
for analysis. Apart from the hazards of transporting flu-
ids such as blood, the integrity of such biosamples could 
become questionable when transported in sub-standard 
conditions. This casts serious doubt on the value of col-
lecting biosamples under such conditions.
Some students without transport do have a prob-
lem. It is unethical I think, for HIV samples to be 
carried in glass bottles using public transport… 
because the hospitals are far away from where 
they are based [university]. They are not allowed 
to analyze any of the blood in the hospitals. The 
laboratory is always busy so we have to carry the 
samples back to campus laboratories (19).
The implications were that some stakeholders (in this 
case postgraduate students) were not treated fairly as 
researchers in biobanking. This raises ethical and legal 
concerns.
Challenges with sample and data sharing
From a legal perspective, the South African Material 
Transfer Agreement of Human Biological Materials 
(SA MTA 2018) is a ‘a contract governing the transfer 
of materials between organisations and /or institutions’ 
and provides a framework for ‘providers and recipients 
of the biological material for use in research or clinical 
trials under the auspices of the Health Research Ethics 
Committees’ in South Africa [23]. Additionally South 
African legislation clearly prohibits commercialization 
of body parts or blood and blood products [5].
While the SA MTA (2018) [23] provides a legal solu-
tion to the sharing of biospecimens with third parties, 
some respondents (REC members, researchers) high-
lighted the limitations of the current document.
It is un-operational at this moment in time. Now 
having a MTA is correct. We are absolutely in 
favour of that, we think it is absolutely appropriate 
but the way the offering was provided was terrible, 
we can’t operationalize that (22).
An MTA should clearly specify the roles and respon-
sibilities of each identified stakeholder, including the 
sender and the recipient. It is equally important that 
such a document gets ‘buy-in’ or support from all 
stakeholders, including research participants. One 
respondent used the Malawian experience to articu-
late how legislation was developed in that country to 
respond to the uncontrolled flow of biospecimens out 
of the country.
There were all sorts of rumours that some of the 
researchers from the West who had collected sam-
ples from Malawi and shipped them to the West, 
were selling those samples to other researchers to do 
their studies, in a way Malawi did not benefit from… 
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at the end of the day, it became like a commercial 
activity and  those that were benefitting were actu-
ally the researchers that came from the West, to col-
lect those samples from Malawi (9).
One of the potential unanticipated outcomes of sample 
and data sharing could be possible commercialization of 
biosamples, as articulated in the above quote. Apart from 
this comment, none of the other respondents indicated 
that commercialization of biosamples was an ethical 
issue to consider in biobanking. It should be noted that 
the interview schedule did not include any probes on 
the commercialization of biosamples.
Suboptimal strategies for benefit sharing
There was inconsistency among respondents on the 
notion of benefit sharing in biobanking, in response to 
the following questions: “What is your understanding of 
benefit sharing? How should this be implemented?”.
You could be [involved in  biobanking] for cancer 
research and if you come up with a cure or some-
thing happens from what you have found, there 
should be some benefit for the community from 
which the samples came (16).
There were strong views on parachute or helicopter 
research where respondents reported that research-
ers from the global north, used developing countries as 
biosample extraction depots, with very little considera-
tion for benefit sharing or developing local capacity in 
biobanking research.
We often see people doing benefit sharing  [efforts] 
in communities. So people come in from outside 
Africa and they say, we will do a workshop for you. 
They have decided what the contents of the work-
shop are, they have decided that we need that work-
shop and often the workshop is repeated stuff that 
we have [been] taught here long ago, or it is not rel-
evant. So there is lots of benefit sharing as collabora-
tors and participants in South Africa but very little, 
real benefit sharing that I see (21).
Other views alluded to statements in the consent docu-
ment that should explicitly outline the biobank’s posi-
tion on benefit sharing. One respondent further pointed 
out that an academic biobank whose sole purpose was 
to facilitate sharing of biosamples for research pur-
poses would not be involved in benefit sharing efforts. 
The responsibility for devising benefit sharing plans, in 
that scenario, would lie with the individual researchers 
who use the stored biosamples. Thus the notion of ben-
efit sharing requires a wider conversation involving all 
stakeholders.
I think benefit sharing should not be a single eth-
ics committee responsibility. I think that needs a 
national discussion around biobanking per se and 
how we as a country look to biobanking principles 
and benefit sharing (22).
Such conversations should include community and 
other stakeholder engagements as well.
Suboptimal processes for return of results
Similarly challenges were noted with some respondents’ 
understanding of return of results or the practicality of 
this process. In response to the question, What is your 
understanding of return of results?, less than a third of 
the study population (researchers, clinicians, biobankers, 
REC members) were able to articulate some understand-
ing of the notion of return of results.
We don’t do enough to interrogate return of results 
with research for future samples. I am trying to think 
if we have asked about incidental findings being 
returned and I have to admit, we don’t interrogate 
that enough (24).
For those respondents who could articulate an under-
standing of return of results, it was clear that researchers 
had a moral obligation to return results that were clini-
cally actionable. However, there were no clear processes 
for how this should be done, that is, should results be 
returned to the biobank to return to the participant or 
returned directly to the participant? Clearly this issue 
needs to be interrogated in the governance frameworks 
for biobanking practice.
It was also seen as necessary to define the target group 
and devise a strategy for return of results, as suggested by 
one respondent:
One must define the target groups that could or should 
benefit from the return of results. The kind of results to 
be returned must be appropriate for the target group. The 
following is not a complete list:
 (i) The scientific community – publications, congress 
proceedings, internet.
 (ii) General public or society – publication of biobank 
activities in non-scientific publications, e.g., public 
websites, annual reports, university-based e.g., Fac-
ulty publications, open media, information sheets, 
brochures.
 (iii) Selected target groups, including clinicians, 
patients, participants, communities, e.g. CANSA, 
postgraduate students doing biobank science 
projects, undergraduate students who visit our 
biobank. (5)
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Improving biobanking practice
In response to the question: “How do we improve 
biobanking practice in the country?”, respondents 
(biobankers) highlighted the value of proper govern-
ance structures with identified leadership, clear roles 
and responsibilities for sample collection, best practices 
for sample storage, access and sharing. Overall the high-
lighted themes suggested a review of biobanking govern-
ance so that some minimum standards can be set across 
the various settings where the study participants are 
based.
The need for and the role of ongoing educational efforts 
were identified as possible ways of improving under-
standing of biobanking in the country.
I think the knowledge gaps starts for many people 
at a very basic level. Just understanding what is a 
biobank and what a biobank is all about, the differ-
ent types of biobanking. For example, research ethics 
committees need to know what to look for when they 
have to approve a biobank application. Patients. 
and the public need to understand what biobanking 
is all about. It would be important to identify dif-
ferent needs for knowledge at different levels. So [a] 
general then focused knowledge distribution and 
training component is important. Target specific role 
players and stakeholders (5).
Discussion
Emergent themes in this study suggested an inconsistent 
understanding of ethical considerations in biobanking. 
This finding is supported by Pawlikowski et al., who also 
reported some inconsistencies in biobanking practice in 
Poland [24]. The reported inconsistencies in biobank-
ing practice across different settings in South Africa 
suggested that there are significant gaps in stakeholder 
(researcher, biobanker, clinician, nurse, postgraduate stu-
dents, REC member) awareness in knowledge of ethics 
required for biobanking.
Dilution of ethics accountability in biobanking
Another theme highlighted the disconnect between 
biobank researchers and biosample donors and that 
this divide could create a distance in the relation-
ship between the biobank and research participants or 
donors. This in turn could impact and possibly dilute eth-
ics accountability and oversight on the part of biobank 
researchers. Improving understanding of the ethics 
of biobanking could be facilitated by acknowledging 
the distance created by biosamples in the relationship 
between  the biobank researchers and donors. This dis-
tance is increased when samples are shared globally and 
sensitivity to ethical oversight may be further diluted. 
The Sanger case highlighted earlier, is one such exam-
ple of the consequences of lapses in ethical oversight. In 
particular, the Sanger case [7, 10, 11]. Illustrates the com-
plexities in biobanking efforts even when data protection 
measures are in place.
Heterogeneity in biobanking practice
Previous empirical research on the ELSI of biobanking 
in South Africa highlighted the need to understand the 
context of biobanking practice and the need to engage 
with stakeholders such as researchers and communities 
[3, 12, 16–19]. This study goes beyond previous empiri-
cal evidence in that while there is an acknowledgement of 
the complexities in biobanking practice, ‘ELSI literature 
on biobanking has largely focused on issues associated 
with a biobank’s relationship to its contributors’, [and] 
little attention has been placed on the people involved in 
the  operationalization and management of the biobank 
[25]. This study reiterated the persistent heterogeneity 
in biobanking practice reported in a previous study [12] 
but further illustrated the different challenges that could 
occur, depending on where the study participants were 
based and what their roles were.
Multiplicity in stakeholder roles in biobanking
The multiple roles played by study participants 
(researcher, biobanker, clinician, REC member) reflected 
the added layer of complexity to biobanking practice. 
These roles, e.g. clinician/ researcher could potentially 
be contradictory, specifically with regards to the ethical 
requirements from a clinical and biobanking research 
perspective. An example of such possible contradiction 
could be where the clinician responsible for clinical care 
also needs to collect biospecimens for unknown research 
purposes. How does the clinician /researcher navigate 
the ethical requirements for different purposes? What 
supportive processes are in place to guide the clinician/
researcher in these dual roles?. How does this differ 
when the researcher is in a biobank interacting with bio-
specimens only or when a researcher is only using bio-
specimens obtained from a biobank in the absence of a 
relationship with the donor? What ethics capacity devel-
opment initiatives are in place? This clearly indicates that 
more effort needs to be invested in recognizing these 
multiple roles that stakeholders occupy.
We will now focus on some of the specific ethico-legal 
aspects highlighted in the study findings.
The need for consistency in governance processes
While biobankers expressed good governance practices, 
the reported challenges by postgraduate students in col-
lecting and transporting biological biospecimens raise 
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both ethical and legal concerns. Soo et  al.also argue 
that collection and storage of biosamples that are not 
aligned to best practice models could threaten the value 
of biobanking research [26].  The reported challenges in 
this study reiterate the need for national legislation on a 
minimum set standards for the collection of biosamples 
[3, 6, 27] irrespective of the context of sample collection. 
This includes the need for oversight in protecting par-
ticipants’ interests and rights. Participants’ privacy and 
confidentiality should be adequately addressed irrespec-
tive of whether the sample is collected and processed in a 
biobank or simply collected from routine clinical proce-
dures and re-purposed for research.
The need for robust governance structures and pro-
cesses in South Africa is also supported by other 
empirical studies [12, 19] and given the current lack of 
‘regulation or governance of biobanking’ from a legal 
perspective in South Africa, more effort is required to 
strengthen legislation on biobanking in the country. This 
study highlighted that these are persistent challenges that 
have not been adequately addressed, although POPIA 
(2013) does provide some direction in this area. Thus, 
the need to increase stakeholder awareness of the ethical 
implications of sample and data storage and sharing, and 
the value of proper governance structures and processes 
to facilitate access and sharing of biosamples, should be 
an urgent consideration.
Consent
A clearly stipulated governance framework or lack 
thereof could have an impact on the nature and value 
placed on obtaining consent from research participants. 
Respondents reported challenges in operationalizing the 
consent process with research participants (where per-
ceived limited research participant understanding was 
cited). This coupled with inconsistencies in respondents’ 
understanding of consent models illustrated the need to 
re-focus attention on how consent is operationalised in 
biobanking.
The study findings suggested that understanding of 
consent becomes more diluted when the stakeholder is 
further from the research participant, as illustrated ear-
lier. This would have important ethical implications for 
how biosamples are processed, stored and shared. How-
ever, the study findings also demonstrate that a clearly 
defined consent process does not negate the other ethi-
cal issues related to biosample collection and storage. 
Engagement with the consent process, including the 
selection of an appropriate consent model would be 
critical for biobanking research. It is therefore necessary 
to unpack the challenges highlighted in this study with 
regards to the use of specific and broad consent.
Broad consent versus tiered consent
It should be noted that respondents in this study were 
merely asked about the ethical concerns in biobanking 
research. No specific model of consent was presented to 
the respondents, yet those who were aware of consent 
models, were mostly able to discuss the merits of a broad 
consent model. This could possibly be attributed to the 
way in which broad consent facilitates data and sample 
collection for researchers at the expense of suboptimal 
participant autonomy as well as the prominence accorded 
to broad consent in the biobanking literature.
One interviewee in this study highlighted the skewed 
dependence on the use of broad consent in biobanking 
research. While this model of broad consent is generally 
accepted [28] and supported in some circles in biobank-
ing practice in South Africa [29], there is ongoing debate 
on its relevance and appropriateness. The lack of clear 
directives for biobanking research in current legislation 
and guidelines, create opportunities for different inter-
pretations of the legal position in South Africa, as alluded 
to earlier. Staunton et al., argued that Sect. 15 of POPIA 
(2013) allows for broad consent to be taken at the out-
set and that specific consent would ‘stifle current and 
future research and innovation’ because of the challenges 
associated with re-contacting and re-consenting partici-
pants [29]. Thaldar and Townsend counter argued that 
POPIA (2013) allows for specific consent only and while 
‘genomic research is in the public interest’, the ‘protection 
of research participants’ privacy rights in their genomic 
information’ cannot be undermined by broad consent 
processes [30].
Similarly, questions are raised as to whether broad con-
sent is truly informed and whether it allows for more or 
less researcher accountability to provide maximum par-
ticipant information [7, 31, 32]. Stakeholders (such as 
biobankers, clinicians, researchers, REC members). need 
to consider the following: does broad consent include 
possible future commercialization of the shared biosam-
ples? To what extent does the notion of benefit sharing 
become eroded when broad consent is used? What are 
researchers’ ethical obligations for benefit sharing when 
broad consent is used?
Despite these debates, researchers will need to comply 
with the Protection of Personal Information Act (2014) 
[21], given that the legal requirements for consent in 
research will dictate the model of consent to be used in 
South Africa. This creates an obligation to act in the best 
interests of research participants/biospecimen donors, to 
ensure an authentic consent process is followed and that 
participant privacy and confidentiality are upheld [33]. A 
balance is therefore required for an appropriate consent 
process that would ensure protection of individual and 
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community rights while maximizing optimal research 
benefits [33, 34].
There is a need for ‘ongoing [consent] processes [that] 
should address how each individual participant may be 
assured autonomy, agency and individualised choice’ 
[35]. A combination of consent options, articulated in a 
tiered consent model might be a plausible compromise as 
proposed by some authors for genomic research in Africa 
[36, 37]. A tiered consent model could optimize par-
ticipant autonomy while promoting scientific progress, 
despite its known shortcomings (such as resource con-
straints for tracking individual participant’s choices [38]. 
A tiered consent model could address some of the per-
sistent challenges that have been identified by this study. 
More importantly a discussion around consent options 
in biobanking, both from a legal and ethical dimension 
could facilitate ongoing stakeholder engagement so as to 
identify ways to overcome these challenges. This high-
lights the need for ongoing ethics capacity building that 
should be included in the governance framework of the 
biobank.
Re‑consent involving minors
Another theme emerging from this study related to re-
consenting minors who reached the independent age of 
consent (≥ 18 years). Respondents reported not knowing 
how to deal with re-consent related to children involved 
in biobanking research. This study finding is consistent 
with other studies that outline the need to consider the 
rights of the child participant [39, 40]. While a re-con-
senting process should be put in place for children who 
reach the age of independent consent so as to uphold 
their rights and interests [39, 41], stakeholders should 
also receive educational support and information on how 
to operationalize this process.
Benefit sharing
Although the study findings indicated inconsistencies 
in understanding and defining the concept of benefit 
sharing, some respondents were able to identify possi-
ble strategies that could be beneficial to individuals and 
communities. This finding is consistent with an earlier 
study that also highlighted the need for stakeholders to 
engage in benefit sharing initiatives [12]. Benefit sharing 
in research remains contentious [42, 43]. This suggests 
that the nature and scope of benefit sharing requires 
more attention [44] and that further research is required 
in this area. One possible source of guidance for benefit 
sharing could be Sect. 7 of the SA MTA (2018). Although 
the reported shortcomings of the document are noted, 
this section does highlight the need for contracting par-
ties to identify ways of sharing benefits that should be 
negotiated before the transfer of such material [23]. The 
San Code on Research Ethics also highlights benefit shar-
ing initiatives such as co-creation of research for knowl-
edge production and shared opportunities for skills 
transfer and local capacity building [13].
Additionally a tiered consent model could allow for the 
individual and the community’s ‘specific choices to be 
voiced on benefit sharing’ [8], however the limitation of 
this approach should be noted, specifically in cases where 
communities have little bargaining power  on  issues 
related to benefit sharing.
Benefit sharing is particularly important in the con-
text of commercialisation where participants in previous 
studies expressed a desire to share in profits generated 
[3]. Again, there is a need for ongoing stakeholder aware-
ness on the scope and nature of benefit sharing to ensure 
that this does not remain an aspiration but rather is 
implementable in local settings.
Commercialization of biospecimens
Although the SA MTA (2018) indicates in Sect.  17.2 
that ‘neither party may assign or cede any benefit, obli-
gation or interest it may have in this agreement to any 
other person without the prior written consent of the 
other party and the approval of the HREC’ [23], research 
ethics guidance documents are not explicit about com-
mercialisation. The fact that commercialization of bio-
specimens  (involving researchers) was not highlighted 
as a prominent ethical concern in this study, is prob-
lematic in light of the legislative loopholes with respect 
to material transfer in South Africa and the recent case 
of the alleged misuse of South African data and samples 
by the Wellcome Sanger Institute in the UK [7, 10, 11]. 
This incident has highlighted the global challenges with 
the  governance of data and sample sharing when this 
occurs in the absence of respect for research participants, 
research collaborators and collaborating institutions [8].
The Sanger Institute debacle could have triggered fur-
ther investigations into commercialisation in biobank-
ing research by the affected research collaborators. The 
findings of such investigations are yet to be disclosed 
publicly. In our study, one can only speculate that com-
mercialization was not fully interrogated from an ethics 
perspective, because South African researchers could 
have a disproportionate dependence on collaborators in 
developed countries for funding and resources or this 
could possibly be due to the asymmetrical power rela-
tionships that evolve in some international collaborations 
[45, 46]. Possible commercialization of biosamples as an 
ethical concern, requires further debate and research 
in South Africa. It is imperative that a well-thought out 
governance framework for research related biobanking 
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consider mechanisms to protect participants from pos-
sible exploitation [47, 48] or commercialization of shared 
biosamples. This needs to be supported by ongoing 
efforts to strengthen stakeholder awareness so as to miti-
gate possible commercialization of biospecimens.
Return of results
Interestingly, return of results could be regarded as a 
form of benefit sharing too. The reported challenges 
in the return of results in this study are consistent with 
other published findings in that there is an urgent need 
to identify ways to operationalize the concept of return 
of results to individual participants [49–51]. Returning 
results to research participants is seen as showing respect 
for participant autonomy and interests [52]. However, the 
notion of benefit sharing and return of results must also 
take into account the challenges that can occur once data 
has been anonymized and cannot be traced back to the 
research participants.
Overall the inconsistencies in participants’ understand-
ing of ethical considerations in biobanking, as reported in 
this study, are not unique. Other studies also highlighted 
ongoing challenges in stakeholder engagement with 
ethical issues. Goisauf et  al., reported that participants 
in their study sought information (from national and 
international guidelines) and support (from helpdesks) 
to design and improve informed consent documents 
[53]. Nansumba et al., added that given the ‘disparities in 
research infrastructure and capacity’ in Lower- and Mid-
dle-Income Countries (LMIC) settings, there is a compel-
ling need for education related to the science and ethical 
dimensions of  biobanking [54]. Similarly, de Vries et al., 
highlighted the need for REC members to engage with 
training efforts for the review of genomic and biobank-
ing research [2]. These comments suggest that stake-
holder skills and preparedness for working in the world 
of biobanking requires ongoing review and increased 
access to educational courses and workshops on skills 
development.
The need to build ethics capacity in biobanking
We further contend that to focus on expanding and 
improving the environment for biobanking without 
building adequate capacity in the very people entrusted 
to engage and manage this process, remains an ethical 
concern. Additionally, there are legal implications when 
a workforce has gaps in knowledge related to the  ethi-
cal aspects in the identified field. One of the important 
legal requirements for health-related research in South 
Africa is the need for researcher competence that is com-
plemented by ongoing basic training in research ethics 
[5, 22] that would ensure awareness of   ethics in general 
as well as ethics compliance in practice. Such training 
should also highlight the need for further consultation, 
communication and collaboration with other relevant 
stakeholders in biobanking. These could include commu-
nity engagement efforts, legal and ethics related advice 
and science communication. All of these issues further 
reiterate the need for a multidisciplinary approach to 
biobanking.
One finding to emerge from this study is the need for 
specific training that is tailored for the different layers 
and levels of stakeholders involved in biobanking. Stake-
holders require ongoing support and training to engage 
meaningfully with the ethical dimensions and legal impli-
cations of biobanking. There is an urgent need to review 
the  availability and accessibility of training opportuni-
ties in order to close this identified knowledge gap. A 
review of the current platforms for stakeholder training 
is required as well as an assessment of the appropriate-
ness of these programmes to meet the diverse needs of 
individuals. Training programmes in biobanking that are 
tailored to respond to the ethical and legal challenges in 
local settings could be of greater value to stakeholders, 
thus international training courses that are not contex-
tualized to local settings may not be appropriate, and a 
one ‘size fits all’ training approach should definitely be 
avoided.
There is thus an urgent need to explore opportunities 
such as investments in educational training that could 
form part of capacity development to improve stake-
holder understanding of these important, crucial implica-
tions for successful and sustainable biobanking initiatives 
and practices in South Africa.
Limitations of the study
These findings provided a unique lens into the complex 
nature of biobanking research that occurs in various for-
mal and informal settings. Given that this study focused 
on eliciting stakeholder perspectives on ethico-legal ethi-
cal considerations in biobanking research in South 
Africa, its generalizability may be limited to similar 
LMIC settings. Another limitation is that not all possi-
ble stakeholders formed part of the study. More research 
is required to determine community and research par-
ticipants’ perspectives, as stakeholders in biobanking 
research. Future research in this area should also include 
policy makers, national regulators and civil society mem-
bers. This study did not sufficiently explore the concept 
of commercialisation in biobanking. Future research to 
unpack the concept of commercialisation in biobanking 
in South Africa is necessary.
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Conclusion
Overall, the study findings indicated inconsistencies in 
stakeholder understanding of ethico-legal considerations 
related to biobanking in South Africa. This necessitates 
the need for ethics capacity building for the identified 
stakeholders in biobanking. One plausible suggestion 
could be training opportunities that are tailored to meet 
the local needs of these stakeholders.
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